

OPEN PEER REVIEW

# Access to Medicines and Intellectual Property Law: Balancing Innovation and Public Health

Mohammad Rauf<sup>1</sup>  Rajesh Tamang<sup>\*2</sup> <sup>1</sup> Faculty of Law, Rajiv Gandhi University, India<sup>2</sup> Department of Law and Political Science, Aligarh Muslim University, Aligarh, India


\* Corresponding author email address: rajeshtamang@gmail.com

Received: 2023-05-12

Revised: 2023-06-12


Accepted: 2023-06-16

Published: 2023-07-01

**EDITOR:**Jingjing Wang 

Law School, Peking University (PKU), Peking, China

jingwang@vip.sina.com

**REVIEWER 1:**Agwu Sunday Okoro 

Lecturer &amp; Clinical Law Administrator at Baze University Abuja, Abuja, Nigeria

agwuokoro@gmail.com

**REVIEWER 2:**Zeynep Karal 

Department of Computer and Instructional Technologies Education, Trabzon University, Trabzon, Türkiye

zeynepkaral@trabzon.edu.tr

## 1. Round 1

### 1.1. Reviewer 1

Reviewer:

The paper should delve deeper into the mechanism by which IP rights specifically foster or hinder innovation in the pharmaceutical industry. Including case studies or empirical data could strengthen this argument.

While the paper discusses global cooperation, it could benefit from a more explicit analysis of how IP law reform can address global health inequities. Incorporating a global health perspective would highlight the international implications of national IP policies.

Expanding the discussion on innovative IP management strategies, such as patent pools and licensing agreements, could offer novel solutions to the challenge of balancing innovation with access. Detailing how these strategies have been implemented and their outcomes could provide valuable insights for future policy.

Authors revised the manuscript and uploaded the document.

### 1.2. Reviewer 2

Reviewer:

The discussion on stakeholder perspectives is valuable but could be improved by including more direct quotes from interviewees. This would add depth and authenticity to the representation of diverse viewpoints.

The paper could incorporate an economic analysis of the impact of IP laws on drug pricing and access. This could include an evaluation of cost-effectiveness and the economic burden of diseases, providing a more comprehensive view of the issues at stake.

Authors revised the manuscript and uploaded the document.

## 2. Revised

Editor's decision: Accepted.

Editor in Chief's decision: Accepted.